CNSP - CNS gives timeline update for Berubicin trial

CNS Pharmaceuticals (CNSP) indicated that the clinical program for Berubicin is on track to start enrolling patients in March 2021.CNS' lead product candidate, Berubicin, is a novel anthracycline and the first anthracycline to cross the blood-brain barrier. It is in development for the treatment of a number of serious brain and CNS oncology indications.The company intends to enroll subjects across about 35 clinical sites in the U.S., with 21 sites currently confirmed and in a start-up process.  The company also plans to expand the trial into western Europe.The potentially pivotal trial is an adaptive, multicenter, open-label, randomized and controlled study in adult patients with recurrent glioblastoma multiforme (WHO Grade IV) after failure of standard first-line therapy, with the primary endpoint of Overall Survival.Shares up nearly 2% premarket.

For further details see:

CNS gives timeline update for Berubicin trial